Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura
Lucas Kühne(University of Cologne), Paul T. Brinkkoetter(University of Cologne), Jessica Kaufeld(Medizinische Hochschule Hannover), Holger Hägele(Munich University of Applied Sciences), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Dennis A. Eichenauer(University of Cologne), Jan Menne, Linus A. Völker(University of Cologne), Thomas Osterholt(University of Cologne), Paul Knöbl(Medical University of Vienna), Marcus Bieringer(Helios Hospital Berlin-Buch), Ulf Schoenermarck(LMU Klinikum), Ralph Wendt(Klinikum St. Georg)
Cited by 1
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
|Blood Cancer Journal|2015|273